In Situ hybridization market.

The market for in situ hybridization is expanding gradually thanks to developments in

genetic and molecular biology. This method is essential for understanding biological
activities, detecting genetic disorders, and researching patterns of gene expression.
Growing prevalence of genetic disorders, growing need for customized therapy, and
continuous technological advancements improving test sensitivity and specificity are
major drivers of market expansion. Furthermore, by encouraging the development of
cutting-edge in situ hybridization methods and applications, partnerships between
academic institutions, pharmaceutical companies, and research organizations support
the expansion of the industry.

Market Drivers:
 Advancement in molecular biology is anticipated to be a major driver of
growth in the In situ hybridization market.

The market for in situ hybridization is expanding due to developments in molecular

biology, including the creation of automated detection methods and more sensitive
probes. The precision, speed, and scalability of in situ hybridization techniques have
been greatly improved by these developments, making them indispensable for
researching gene expression, detecting genetic anomalies, and developing personalized
medical strategies. The need for in situ hybridization technologies in both research and
clinical contexts is being driven by researchers' and healthcare professionals' growing
reliance on these cutting-edge molecular biology tools to obtain deeper insights into
cellular functions, disease causes, and therapeutic targets.

In April 2023,Agilent Technologies Inc. and Theragen Bio, a South Korean company,
inked a Memorandum of Understanding to advance bioinformatic (BI) solutions and
precision oncology. Agilent and Theragen Bio have entered into a partnership
agreement whereby they would pool their skills in cancer genomic profiling (CGP)
design, engineering know-how, and software proficiency to enhance targeted analysis
capabilities and expedite treatment decisions. Through high throughput sequencing of
DNA and RNA bases in parallel, Agilent's SureSelect Cancer CGP test leverages next
generation sequencing (NGS) to revolutionize translational research and clinical trials in
oncology while minimizing hands-on time to maximize lab productivity.

 Technological advancements are anticipated to be the driving force

behind the growth of the In situ hybridization market.
The in situ hybridization industry is expanding due to developments in technology,
including the creation of more sensitive probes, automation platforms, and digital
imaging systems. The precision, velocity, and expandability of in situ hybridization
methods have been greatly enhanced by these developments, becoming them
indispensable for examining gene expression patterns, identifying genetic anomalies,
and informing personalized medicine strategies. In situ hybridization is now a vital tool
for molecular biology research, clinical diagnostics, and drug development, thanks to
the integration of cutting-edge technologies that have expedited workflows, decreased
assay variability, and improved data processing capabilities. This has led to the market's
increase.
In May 2023, With the release of an RNAscope multiomic workflow for the Standard
BioTools HyperionTM Imaging System, Bio-Techne announced the expansion of its
RNAscopeTM in situ hybridization (ISH) portfolio, which is branded under the Advanced
Cell Diagnostics (ACD) brand.Visualizing highly multiplexed RNA biomarkers with the
Hyperion XTi or previous versions of the Hyperion Imaging System is made possible by
the new RNAscope HiPlex12 Flex Kit. Using Imaging Mass Cytometry, this technology
allows for the simultaneous identification and precise quantification of over 40
biomarkers from any tissue sample in a single imaging phase.Using standard formalin-
fixed paraffin-embedded (FFPE) tissue pathology, the new multiomic workflow will allow
researchers to reveal changes in cell phenotypes and function across a wide range of
diseases by offering a straightforward and easy way to incorporate prelabelled and user-
conjugated Maxpar Antibodies from Standard BioTools during sample preparation.

 Rising prevalence of genetic disorders is expected to drive growth in

the In situ hybridization market.
The global increase in the frequency of genetic disorders is one of the main factors
propelling the in situ hybridization market. The need for precise and trustworthy
diagnostic methods, such as in situ hybridization, is rising as more people are receiving
diagnoses for genetic disorders. With the use of this technology, genetic anomalies can
be detected at the cellular level, offering vital insights into the mechanisms underlying
disease and informing individualized treatment plans. In situ hybridization is essential
for genetic testing, clinical research, and medicinal development, and its growing
demand for accurate molecular diagnostics drives the market.

Asia Pacific region is expected to grow significantly.

The in situ hybridization market is expanding significantly in the Asia-Pacific region as a
result of a number of important factors. The market is expanding as a result of quick
improvements in healthcare infrastructure, higher spending on R&D, and growing public
awareness of personalized medicine. In addition, a sizable patient population and the
increasing incidence of genetic illnesses are driving up demand for sophisticated
molecular diagnostic methods such as in situ hybridization. In addition, partnerships
among universities, pharmaceutical firms, and governments are encouraging innovation
and technology transfer, which is driving the Asia-Pacific in situ hybridization market's
expansion.

Market Challenges:

 Complexity and time-consuming nature of the technique can constrain

the market for In situ hybridization.
The in situ hybridization process is time-consuming and complex, which presents a
significant hurdle in the market. In situ hybridization experiments can be expensive and
resource-intensive to perform since they need specific knowledge, tools, and materials.
Furthermore, there may be difficulties in interpreting the findings and analyzing the
data, particularly when trying to spot small variations in gene expression or genetic
anomalies. Gaining greater acceptance and expanding the business will require
resolving these technical issues and enhancing assay automation and uniformity.

Market Development:
 July 2023- Lunaphore Technologies SA was bought by Bio-Techne Corporation.In
order to strengthen their leadership in spatial biology in the translational and clinical
research markets, Bio-Techne and Lunaphore are joining forces.Among the
instruments offered by Lunaphore is COMETTM, an end-to-end platform for spatial
biology that combines imaging, tissue staining, and image preprocessing into a fully
automated, high-throughput device that offers unparalleled scalability,
reproducibility, and tissue morphology preservation. COMET's exceptional tissue
profiling capabilities, which are intended for use with conventional pathology slides,
allow for nearly infinite plex by analyzing 40 distinct spatial biomarkers per sample
in each automated run.
 May 2023- In order to help patients with lung and breast cancer in more than 30
countries across Latin America, Africa, the Middle East, and Asia who have previously
had limited or no access to advanced genomic testing, Pfizer and Thermo Fisher
Scientific Inc. announced that they have entered into a collaboration agreement.
Having access to local NGS testing can facilitate quicker gene analysis, enabling
medical professionals to choose the best course of treatment for each patient.
Market Segmentation:

 By Product Type
o Antiparasitic
o Anti-infectives
o Vaccines
o NSAIDs
o Others
 By Service Type
o In House
o Contract Outsourcing
 Contract Development
 Contract Manufacturing
 By Synthesis Type
o OMICS Chemical Based API
o Biological API
o Highly Potent API (HPAPI)
 By Route of administration
o Oral
o Injectable
o Topical
o Others
 By Geography
o North America
 United States
 Canada
 Mexico
o South America
 Brazil
 Argentina
 Others
o Europe
 United Kingdom
 Germany
 France
 Italy
 Spain
 Others
o Middle East and Africa
 Saudi Arabia
 UAE
 Others
o Asia Pacific
 Japan
 China
 India
 South Korea
 Taiwan
 Thailand
 Indonesia
 Others

Companies mentioned:
o Sequent Scientific Ltd. (Alivira Animal Health Limited)
o Stanley Black & Decker (Excel Industries Limited)
o Ofichem Group
o Menadione
o SUANFARMA
o NGL Fine-Chem Ltd.
o FIS - Fabbrica Italiana Sintetici S.p.A.
o Sidhiv Pharma
o Chempro Pharma Private Limited
o AMGIS Lifescience Ltd
T ABLE OF CONT E NT S

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Russia-Ukraine War Impact Analysis
5. IN SITU HYBRIDIZATION MARKET, BY PRODUCT

5.1. Introduction
5.2. Kits and Reagents
5.2.1. Market Trends and Opportunities
5.2.2. Growth Prospects
5.3. Software and Services
5.3.1. Market Trends and Opportunities
5.3.2. Growth Prospects
5.4. Other Products
5.4.1. Market Trends and Opportunities
5.4.2. Growth Prospects

6. IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY

6.1. Introduction
6.2. Fluorescence In Situ Hybridization Market (FISH)
6.2.1. Market Trends and Opportunities
6.2.2. Growth Prospects
6.2.3. DNA-FISH
6.2.4. RNA-FISH
6.3. Chromogenic In Situ Hybridization Market (CISH)
6.3.1. Market Trends and Opportunities
6.3.2. Growth Prospects

7. IN SITU HYBRIDIZATION MARKET, BY APPLICATION

7.1. Introduction
7.2. Cancer Diagnosis
7.2.1. Market Trends and Opportunities
7.2.2. Growth Prospects
7.3. Immunology
7.3.1. Market Trends and Opportunities
7.3.2. Growth Prospects
7.4. Neuroscience
7.4.1. Market Trends and Opportunities
7.4.2. Growth Prospects
7.5. Cytology
7.5.1. Market Trends and Opportunities
7.5.2. Growth Prospects
7.6. Infectious Diseases
7.6.1. Market Trends and Opportunities
7.6.2. Growth Prospects

8. IN SITU HYBRIDIZATION MARKET, BY END-USER

8.1. Introduction
8.2. Molecular Diagnostic Laboratories
8.2.1. Market Trends and Opportunities
8.2.2. Growth Prospects
8.3. Pharmaceutical & Biotechnology Companies
8.3.1. Market Trends and Opportunities
8.3.2. Growth Prospects
8.4. Contract Research Organizations (CROS)
8.4.1. Market Trends and Opportunities
8.4.2. Growth Prospects
8.5. Academic & Research Institutions
8.5.1. Market Trends and Opportunities
8.5.2. Growth Prospects

9. IN SITU HYBRIDIZATION MARKET, BY GEOGRAPHY

9.1. Introduction
9.2. North America
9.2.1. By Product
9.2.2. By Technology
9.2.3. By Application
9.2.4. By End-User
9.2.5. By Country
9.2.5.1. United States
9.2.5.1.1. Market Trends and Opportunities
9.2.5.1.2. Growth Prospects
9.2.5.2. Canada
9.2.5.2.1. Market Trends and Opportunities
9.2.5.2.2. Growth Prospects
9.2.5.3. Mexico
9.2.5.3.1. Market Trends and Opportunities
9.2.5.3.2. Growth Prospects
9.3. South America
9.3.1. By Product
9.3.2. By Technology
9.3.3. By Application
9.3.4. By End-User
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.1.1. Market Trends and Opportunities
9.3.5.1.2. Growth Prospects
9.3.5.2. Argentina
9.3.5.2.1. Market Trends and Opportunities
9.3.5.2.2. Growth Prospects
9.3.5.3. Others
9.3.5.3.1. Market Trends and Opportunities
9.3.5.3.2. Growth Prospects
9.4. Europe
9.4.1. By Product
9.4.2. By Technology
9.4.3. By Application
9.4.4. By End-User
9.4.5. By Country
9.4.5.1. United Kingdom
9.4.5.1.1. Market Trends and Opportunities
9.4.5.1.2. Growth Prospects
9.4.5.2. Germany
9.4.5.2.1. Market Trends and Opportunities
9.4.5.2.2. Growth Prospects
9.4.5.3. France
9.4.5.3.1. Market Trends and Opportunities
9.4.5.3.2. Growth Prospects
9.4.5.4. Italy
9.4.5.4.1. Market Trends and Opportunities
9.4.5.4.2. Growth Prospects
9.4.5.5. Spain
9.4.5.5.1. Market Trends and Opportunities
9.4.5.5.2. Growth Prospects
9.4.5.6. Others
9.4.5.6.1. Market Trends and Opportunities
9.4.5.6.2. Growth Prospects
9.5. Middle East and Africa
9.5.1. By Product
9.5.2. By Technology
9.5.3. By Application
9.5.4. By End-User
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.1.1. Market Trends and Opportunities
9.5.5.1.2. Growth Prospects
9.5.5.2. UAE
9.5.5.2.1. Market Trends and Opportunities
9.5.5.2.2. Growth Prospects
9.5.5.3. Others
9.5.5.3.1. Market Trends and Opportunities
9.5.5.3.2. Growth Prospects
9.6. Asia Pacific
9.6.1. By Product
9.6.2. By Technology
9.6.3. By Application
9.6.4. By End-User
9.6.5. By Country
9.6.5.1. Japan
9.6.5.1.1. Market Trends and Opportunities
9.6.5.1.2. Growth Prospects
9.6.5.2. China
9.6.5.2.1. Market Trends and Opportunities
9.6.5.2.2. Growth Prospects
9.6.5.3. India
9.6.5.3.1. Market Trends and Opportunities
9.6.5.3.2. Growth Prospects
9.6.5.4. South Korea
9.6.5.4.1. Market Trends and Opportunities
9.6.5.4.2. Growth Prospects
9.6.5.5. Taiwan
9.6.5.5.1. Market Trends and Opportunities
9.6.5.5.2. Growth Prospects
9.6.5.6. Thailand
9.6.5.6.1. Market Trends and Opportunities
9.6.5.6.2. Growth Prospects
9.6.5.7. Indonesia
9.6.5.7.1. Market Trends and Opportunities
9.6.5.7.2. Growth Prospects
9.6.5.8. Others
9.6.5.8.1. Market Trends and Opportunities
9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Abbott Laboratories, Inc.

11.2. F.Hoffmann-La Roche Ltd.
11.3. Thermofisher Scientific, Inc.
11.4. Merck KGaA
11.5. Agilent Technologies, Inc.
11.6. Perkin Elmer, Inc.
11.7. Leica Biosystems Nussloch GmbH
11.8. Biogenex Laboratories, Inc.
11.9. Advanced Cell Diagnostics, Inc
11.10. Genemed Biotechnologies, Inc.
11.11. Biocare Medical,LLC.
11.12. Bio Sb, Inc.

https://www.abbott.com/product-list.html

https://diagnostics.roche.com/global/en/products/lab/ish-amplification-kit-
rtd000975.html

https://www.thermofisher.com/in/en/home/life-science/cell-analysis/cellular-imaging.html

https://www.merckmillipore.com/IN/en/products/vMqb.qB.GdEAAAE_Mhd3.Lxj,nav

https://www.agilent.com/en/product/molecular-pathology

https://www.perkinelmer.com/category/products-services

https://shop.leicabiosystems.com/ihc-ish/detection-systems/

https://biogenex.com/technology-ish/

https://acdbio.com/products

https://www.genemed.com/products.html

https://biocare.net/molecular/

https://www.biosb.com/products/